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Abstract The highly infectious nature of tuberculosis (TB) urges the need to increase the efficiency
and rapidity of lab methods. The coexistence of TB and cancer was investigated using Mycobacterium
tuberculosis direct test (MTD) and the mycobacteria growth indicator tube (MGIT), besides the conventional
lab procedures. All assays were performed on 101 patients clinically suspected of having a mycobacterial
infection. Over a period of 4 years, TB was confirmed in 32 patients with malignancy by applying the gold
standard of considering patients with positive culture on Lowenstein–Jensen or MGIT or having any two
or more positive tests as confirmed mycobacterial infection. Among the confirmed cases, the underlying
malignant conditions were hematologic malignancies, bronchogenic carcinoma, and other solid tumors, in
14, 12, and 6 of the patients; respectively. TB developed during cancer chemotherapy in 18 cases (56%),
and was discovered synchronously with malignancy in 14 (44%) patients. The ZN stain revealed acid-fast
bacilli in 15 (47%) cases. The LJ culture was positive in 20 (63%) cases and MGIT was positive in 18 (56%)
cases. Although the MTD test was positive in 18 (56%) of the confirmed TB cases; i.e., it was negative in
14 cases positive by other tests. There was a moderate agreement between results of LJ and MGIT, Kappa
0.396 and ZN and MGIT, Kappa 0.436. There was a weak agreement between results of LJ and MTD, ZN
and MTD, Kappa 0.227 and 0.209; respectively; whereas, no agreement was calculated between MGIT
and MTD Kappa 0.029. The calculation of the combined sensitivity of any two tests was 94%. TB is a
major pathogen in patients with malignant diseases if clinically suspected. Little overlap between different
the
ove thtechnologies used necessitates
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ntroduction
uberculosis is still a leading health problem as reported by the
orld Health Organization (WHO), with an estimated 8 million
ew cases annually. In Egypt, TB prevalence has been estimated to
e 35 cases/100,000 in the year 2004 [1].
The relationship between TB and cancer is of dual nature.
atients with malignant diseases are at increased risk for dis-
ases caused by mycobacteria. Patients with depressed cellular
mmunity such as those who have lymphoproliferative disorders,
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than two groups. Comparison between categorical measurements
was done using the Chi-square or Fisher exact tests, depending58
ransplant patients and patients on immunosuppressive therapy
re at particular risk [2]. Alternatively, TB may occasionally be
isinterpreted as cancer [3]. Furthermore, delay in TB diagnosis
n patients with leukemia and active TB results in transmis-
ion of Mycobacterium tuberculosis to other immunosuppressed
atients [4]. Therefore, baseline TB screening and earlier clinical
ecognition of active disease could reduce healthcare facility-
ssociated transmission of MTB among patients with malignant
iseases.
Conventional laboratory procedures for MTB detection rely
pon microscopic examination for the presence of acid-fast bacilli
AFB), and culture on solid and/or liquid media. Microscopic exam-
nation for AFB is rapid but has a very limited sensitivity. Although
ulture is still the gold standard for diagnosis of TB, it may require
turnaround time of 2–8 weeks [5]. Therefore, Novel TB diag-
ostics have been introduced to aid in earlier and more sensitive
dentification of cases.
The mycobacteria growth indicator tube, a non-radioactive broth
ased culture system is a rapid detection method for isolation of
ycobacteria from clinical specimens [6]. The M. tuberculosis
irect test is an isothermal transcription-mediated amplification sys-
em in which specific mycobacterial 16S rRNA target is amplified
sing DNA intermediaries. In 1999, the Food and Drug Adminis-
ration approved it for the diagnosis of MTB in smear-positive and
negative specimens from patients suspected of having TB [7]. Lit-
le literature showing side by side field performance of these tests in
usceptible cancer patients is available. The aim of the present study
as primarily to assess the demographics of TB infection in patients
ith malignant diseases and secondly to evaluate the role of newer
echniques in the diagnosis of TB in comparison to conventional
aboratory procedures.
atient and methods
his was a prospective study performed at the National Cancer
nstitute (NCI), Cairo University, a university based tertiary care
enter receiving an excess of 15,000 newly diagnosed cases of can-
er each year. The study was approved by the Ethics Committee
f the NCI and an informed written consent was obtained from all
articipants.
tudy design
atients were included in the study if they had clinical symptoms
nd/or radiological evidence suggestive of TB. Cancer patients were
eferred by clinicians to microbiology lab from surgical, medical
nd pediatric oncology departments at National Cancer Institute,
airo University when clinically suspected of having TB infec-
ion. Inclusion criteria were chronic cough for more than 2 weeks,
ecurrent chest infection, dyspnea, hemoptysis, and weight loss.
ll four tests were done for all enrolled cases. A diagnosis of
B was confirmed by applying the gold standard of considering
atients with positive culture and those having two or more tests
ositive. Response to therapy was not considered in the present
tudy.onventional laboratory procedures
pecimens were collected according to the suspected site of disease.
putum samples were obtained on 3 successive days. Bronchoalve-
lar lavage (BAL) fluid was collected during bronchoscopy. Other
o
f
w
c
wH.A. El-Mahallawy et al.
amples included pus, tissue biopsy, and sterile body site fluids.
amples were subjected to direct Ziehl Neelsen (ZN) staining, fol-
owed by decontamination. Tissues were grinded, mixed with sterile
aline before processing. Specimens were digested and decontam-
nated by the N-acetyl-l-cysteine NaOH method. ZN stain was
one again after decontamination. Cultivation of the specimens was
arried out on Lowenstein–Jensen (LJ) screw capped bottles and
ept for 8 weeks [8]. Any growth detected was confirmed by ZN
tain.
ycobacteria growth indicator tube (MGIT)
ubes were supplied by Becton Dickinson Microbiology Systems,
S. Specimen inoculation was carried out as recommended by the
anufacturer [6]. The MGIT contains 4.0 ml of 7H9 broth with
.25% glycerol. The bottom of this tube has a fluorescent indica-
or embedded in silicone. Consumption of oxygen by the growing
ycobacteria activates the indicator, which produces fluorescence
bright orange colors on the bottom and the meniscus) when the
ube is exposed to UV light generated by a 365-nm UV transillumi-
ator. Before inoculation with the processed specimens, the tubes
ave to be supplemented with 0.5 ml of OADC (oleic acid, albumin
bovine], dextrose, catalase) and antibiotics. Tubes were read uti-
izing a UV lamp next to positive and negative controls. Negative
ubes were read weekly for up to 4 weeks. Contamination was sus-
ected if fluorescence occurred within 24–72 h after inoculating the
ubes.
olecular diagnosis
mplified M. tuberculosis direct test (MTD) was purchased from
en-Probe, US. Digested decontaminated samples were stored
t −20 ◦C until the amplification technique was performed. The
mplification assays were run in three separate areas which have
een set up specifically for MTD. The MTD test is an isothermal
ranscription-mediated amplification system based on the reverse
ranscription of mycobacterial-specific rRNA targets, followed by
ranscription of the DNA intermediate template. Subsequent detec-
ion of RNA amplicons is through a hybridization protection assay
sing an acridinium ester-labeled M. tuberculosis complex-specific
NA probe. The MTD test was performed according to the manufac-
urer instructions [9]. Each run included a positive control prepared
rom a suspension of MTB, and a negative control prepared from a
uspension of MOTT. A cutoff value of 30,000RLU was used for
ositive specimens [10].
tatistical methods
tandard descriptive statistical methods were used to describe
he patient population. Numeric data were summarized as
ean ± standard deviation, categorical measurements and percent-
ges. Comparison between two groups for numeric variables was
one using Mann–Whitney test, and Kruskal–Wallis test for moren sample size. The results of TB diagnostic tests were studied
or their strength of agreement using the Kappa coefficient. Data
ere analyzed using Statistical Analysis Systems SPSS in statisti-
al package version 12. All p-values were 2 sided. p-values < 0.05
ere considered significant.
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Table 1 The clinical characteristics, and type of sample of 101
cancer patients clinically suspected of having mycobacterial infec-
tion included in the study.
Parameter Number (%)
Sex
Male 62 (61.4)
Female 39 (38.6)
Age (years)a
44.2 ± 20.4 (2–82)
Diagnosis
Bronchogenic cancer, n = 43 43 (42.6)
Hematologic malignancy, n = 37
ALL 11 (10.9)
AML 4 (4.0)
CML 2 (2.0)
Lymphoma 20 (20.0)
Solid tumors, n = 21 21 (20.8)
Sample
Ascitic fluid 2 (2.0)
BAL 33 (32.7)
CSF 1 (1.0)
Pleural effusion 1 (1.0)
Pus 6 (5.9)
Sputum 55 (54.5)
Table 2 The relation between the results of different tests done
on 101 patients with malignant diseases and clinically suspected to
be tuberculous.
No. of tests positive ZN LJ MGIT MTD No. of cases
15 20 18 30
Four tests + + + + 2
Three tests + + + 1
+ + + 2
+ + + 2
Two tests + + 1
+ + 3
+ + 4
+ + 6
+ + 6
+ + 3
One test + 1
+ 1
One test + 12
ZN + LJ were positive in 7 samples, ZN + MGIT were positive in 8 sam-
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a Values are means ± standard deviations.
Results
This study was carried out on 101 patients in different stages of
malignant diseases clinically suspected of having a mycobacterial
infection during the period from January 2001 to December 2004. Of
the 101 patients, 86 were adults and 15 were children below 18 years.
The bronchogenic carcinoma patients were studied as new cases for
the possibility of TB mimicking a malignant disease, whereas the
other cases were receiving therapy. The clinical characteristics of
101 patients are summarized in Table 1.
Mycobacterial studies
The ZN stain revealed acid-fast bacilli in 15 cases. The LJ culture
was positive in 20 cases. Growth was detected within 10–45 days.
The MGIT tubes were positive in 18 cases. Growth was detected
within 7–13 days. Bacteria or fungi were a source of contamination
in 17/101 samples.
The MTD test was positive in 30 cases, yet it was nega-
tive in 14 other cases that were deemed positive by the other
tests. Twelve cases (5 solid, 4 bronchogenic and 3 hematologic)
were only MTD positive, with all other tests negative. Clinically,
these patients had mild chronic symptoms and were stable with-
out anti-tuberculous treatment. All tests were negative in 57 of
the cases (56%). The relation between the results of different tests
is shown in Table 2. Sensitivity, specificity, positive and negative
predictive values of the different tests are summarized in Table 3.
Tables 4 and 5 illustrate the strength of agreement between different
tests.
D
ples, ZN + MTD were positive in 9 samples, MGIT + LJ were positive in
0 samples, MGIT + MTD were positive in 6 samples, MTD + LJ were
ositive in 10 samples. All tests were negative in 57 of the cases (56%).
onfirmed cases
y applying the golden rule, 32 cases were considered truly hav-
ng mycobacterial infection. This constituted TB attack rate of
.5/1000 new cancer case a year. Pulmonary TB was the most
ommon site of infection (28/32, 88%). Four cases manifested extra-
ulmonary mycobacterial infection, which were meningitis, psoas
bscess, chest wall abscess and laryngeal wound discharge. Among
he confirmed positive cases, hematologic malignancies were the
nderlying disease in 14 patients (5 acute lymphoblastic leukemia,
lymphoma, and 1 acute myeloblastic leukemia), bronchogenic car-
inoma in 12, and in 6 of other solid tumors. The difference between
he three groups was not statistically significant, p = 0.599. Of the 32
onfirmed cases, 26 were adults and 6 were children. TB developed
uring cancer chemotherapy in 56% (n = 18) of cases. TB was dis-
overed synchronously with malignancy in 44% (n = 14) of patients.
he hematological malignancy patients were in a disease remission.
able 3 summarizes the overall sensitivity, specificity, positive and
egative predictive values of the different tests in confirmed cases.
he combined sensitivity of any two tests was 94%.
ast history of TB
ixteen patients (16%) had a past history of tuberculosis and had
reviously received anti-tuberculous treatment (2–10 years before).
f these cases, 9 had bronchogenic carcinoma (56%), 5 had hemato-
ogic malignancies (31%), and 2 cases of solid tumors (13%). Six of
hese patients were confirmed TB positive, while 10 were negative
or TB. The relation between past history of TB, and recurrence of
B with present malignant condition was not statistically significant,
= 0.457.iagnosis of TB can be clinically challenging. M. tuberculosis com-
lex is highly infectious; therefore its diagnosis as early as possible
160 H.A. El-Mahallawy et al.
Table 3 Overall sensitivity, specificity, positive predictive and negative predictive values of the four tests for the confirmed TB cases by
applying the golden rule.
Measurement Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Positive predictive value
(%) (95% CI)
Negative predictive
value (%) (95% CI)
ZN 47 (30–65) 100 (93–100) 100 (75–100) 80 (70–88)
LJ 63 (44–78) 100 (93–100) 100 (80–100) 85 (75–92)
MGIT 56 (38–73) 100 (93–100) 100 (79–100) 84 (74–91)
MTD 56 (38–73) 83 (71–90) 60 (41–77) 80 (68–88)
Table 4 The agreement between MGIT compared to both conventional procedures.
Agreement between tests LJ and MGIT number (%) ZN and MGIT number (%)
Negative Negative 73 (72.2) 76 (75.3)
Negative Positive 8 (7.9) 10 (9.9)
Positive Negative 10 (9.9) 7 (6.9)
10 (9
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appa, measure of agreement. Kappa of LJ and MGIT was 0.396 (moderat
s of paramount importance. In the present study, detection of MTB
as attempted in patients with malignant diseases suspected clin-
cally and/or radiologically of being tuberculous. During 4 years,
01 patients were evaluated for the possible coexistence of cancer
nd TB. Of the 101 cases clinically suspicious for the possibility
f TB, 32 were confirmed positive by applying the golden stan-
ard for TB diagnosis. The most remarkable finding of the present
tudy is the lack of strong agreement between results of different
ests performed. There was a moderate agreement between MGIT
nd conventional tests, and weak agreement between MTD and the
ther three tests.
Considering the results of the four tests together, the expected
cenario of three or four tests positive in confirmed cases was quite
ncommon. Discrepancy between smear positivity and MTD with
ulture was 7 in 20 and 10 in 20; respectively. Similarly, Tueller
t al. [11] reported that only 39% of culture positive pulmonary
B had a positive sputum smear. Smear examination for acid-fast
acilli demonstrated a specificity of 100% in the present study; still
ts value is limited by its low sensitivity. Although ZN has a high pre-
ictive value, a negative AFB smear does not exclude TB, especially
f clinical suspicion is high. Culture of MTB is the gold standard for
iagnosis of TB. It is a much more sensitive test than smear exami-
ation and has been estimated to detect 10–100 viable mycobacteria
er ml of sample and in case of active disease they are found to be
1% sensitive and 98.5% specific [12]. A moderate agreement was
ecorded between LJ and MGIT in the present study. The LJ culture
as positive in 20 cases with growth detected within 10–45 days,
hereas; MGIT tubes were positive in 18 cases detected within
–13 days. So, it is evident that MGIT has the advantage of early
s
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Table 5 The agreement between MTD compared to other TB tests perfo
Agreement between tests LJ and MTD number (%)
Negative Negative 62 (61.4)
Negative Positive 19 (18.8)
Positive Negative 10 (9.9)
Positive Positive 10 (9.9)
appa values were 0.227 (weak agreement), 0.209 (weak agreement) and 0.029 (n
espectively..9) 8 (7.9)
ement) and of ZN and MGIT was 0.436 (moderate agreement).
etection. In conclusion, it was found that MGIT represents a valu-
ble tool in laboratory protocol in conjunction with solid media for
btaining rapid detection of growth from culture positive specimens
nd for better overall sensitivity [13].
In the present study, MTD was positive in 18 of the 32 con-
rmed cases, and was negative in the remaining 14. This high false
egative rate for MTD in the current study in comparison with con-
entional methods does not justify its use as a single test for the
iagnosis of TB. Similarly, false negative results were previously
eported for MTD in comparison with culture [10]. Moreover, it is
greed nowadays that the reliability of amplification methods for
he direct detection of MTB is not as satisfactory as for other micro-
rganisms due to low sensitivity compared with culture and inability
o differentiate dead bacilli from the living [14]. Given the public
ealth concerns and very high morbidity and mortality of TB, the key
spect of MTD performance is the negative predictive value; i.e., it
s critically important that any patient with TB not to be overlooked
10].
Earlier studies had shown high sensitivity and specificity of the
TD test, but that was recorded in smear-positive cases [15]. An
lternative explanation could be related to the fact that MTD specif-
cally detects MTB but not MOTT. A recent study investigated the
se of gene probe in culture positive samples and was able to iden-
ify MTB in 77% of samples, while 23% were identified as MOTT
16]. The MTD assay had a sensitivity of 100 and 75% for acid-fast
mear-positive and -negative respiratory specimens, respectively
10]. In the latter study, reduced sensitivity was seen among acid-fast
mear-negative non-respiratory specimens (63.9%) when compared
o smear-positive specimens (90%).
rmed in the study.
ZN and MTD number (%) MGIT and MTD number (%)
65 (64.4) 59 (58.4)
21 (20.8) 13 (12.9)
6 (5.9) 23 (22.8)
9 (8.9) 6 (5.9)
o agreement) between LJ and MTD, ZN and MTD, and MGIT and MTD;
R[
[
[
[
[
[
[
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In the present study, 12 patients were MTD positive, with other
tests negative. Clinically, these patients had mild chronic symptoms
and were stable without anti-TB treatment. The possibility exists that
these patients were having a subclinical infection. The low speci-
ficity and positive predictive value observed in the present study
would markedly improve if those cases were considered subclinical
cases and excluded out of calculations. In general, the results of the
present study were similar to those of a previous study, reporting
11 discrepant results between cultures and MTD; five false positive
and six false negative results [10].
It is evident from the findings of the current study that TB diag-
nostic tests do not line up perfectly. Thus, the clinician is left with a
judgment call despite the introduction of new technology. One of the
most important criteria for establishing a presumptive diagnosis of
TB is a case definition, which may be based on clinical symptoms,
radiographic signs, risk factors, or a combination of these [15]. Sim-
ilarly, a recent study concluded that a high index of suspicion for
TB and blood culture for MTB provide a simple and non-invasive
diagnostic method to detect disseminated TB [17].
The results of the present study done over 4 years demonstrated
that the TB attack rate at Egyptian National Cancer Institute was
0.5/1000 new cancer cases a year. Similarly, the overall rate of active
tuberculosis during a 4-year study, extending from 2001 to early
2005, was 0.2 in 1000 new cancer diagnoses at a tertiary care referral
cancer center [18]. In a similar study, 56 patients with both TB and
malignancy were identified from January 1989 through December
1994 in a population of 61,931 newly registered cancer patients.
The frequency of TB in cancer patients was 90 per 100,000 [19].
Among the 32 confirmed TB cases, hematological malignancies,
bronchogenic carcinoma, and other solid tumors were the under-
lying malignant diseases in 14 (44%), 12 (37%), 6 (19%) cases;
respectively. In agreement with our findings, De La Rosa et al. [20]
reported the coexistence of cancer and TB infection in 30 patients
with hematological malignancies (63%) and solid organ malignan-
cies (37%). It was concluded that TB in cancer patients occurs at a
nine times greater rate than in the general population and is most fre-
quent in leukemia patients [19]. In regards to the site of the disease,
pulmonary TB was the most common site of infection in the present
study (28/32, 88%). Similarly, Kim et al. [21] reported that the lung
was the most common site of TB involvement (87.8%) in a group
of cancer patients who developed TB while receiving anti-cancer
therapy, which was similar to a group of age- and sex-matched TB
patients without any malignant disease (79.2%).
Although six of the confirmed TB patients had a past history of
TB, yet there were no significant differences between confirmed TB
cases and those who were considered negative in regard to previous
history of TB. On the contrary, the presence of scar tissue suggesting
old TB on radiography was more common in patients with tuber-
culosis receiving anti-cancer chemotherapy (66.7% versus 43.8%,
p = 0.07) [21].
In conclusion, M. tuberculosis is an important pathogen in
patients with malignant diseases and should be promptly searched
for in this population of patients in case of clinical suspicion.
Newer methods of detection of mycobacterial infection can enhance
diagnostic certainty but cannot replace conventional procedures.
Utilization of combination of tests together with consideration of
key clinical characteristics, could improve diagnostic accuracy. The
MGIT test is equivalent to LJ culture; in addition it has the advan-
tage of supplying early results. The MTD represents an important
advance in improving the speed and accuracy of diagnosis of TB,
yet it should be performed in conjunction with microscopy and
culture.
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